| Literature DB >> 33298757 |
Rosa Alessia Battista1, Milena Ferraro, Lucia Oriella Piccioni, Giulia Elvira Malzanni, Mario Bussi.
Abstract
OBJECTIVES: To assess prevalence of Personal Protective Equipment (PPE)-related symptoms and adverse reactions during Coronavirus Disease 2019 pandemics.Entities:
Mesh:
Year: 2021 PMID: 33298757 PMCID: PMC7864606 DOI: 10.1097/JOM.0000000000002100
Source DB: PubMed Journal: J Occup Environ Med ISSN: 1076-2752 Impact factor: 2.306
FIGURE 1Facial dermatosis characterized by erythema and pustules corresponding to cheeks and chin skin usually covered by respirator mask.
FIGURE 2Device-related pressure lesions on auricular, zygoma, and nose bridge associated with use of facial personal protective equipment.
PPE-Related Adverse Reaction in Entire Study Cohort and the Three Subgroups Identified According to Professional Risk Exposure
| Entire Study Cohort ( | Healthcare Staff ( | Public Exposed Work ( | Low External Exposure ( | ||
| Symptoms, | |||||
| Nasal symptoms (one or more of the following) | 306 (80.3) | 168 (90.8) | 28 (90.3) | 110 (66.7) | |
| Nasal obstruction/dyspnea | 248 (65.1) | 136 (73.5) | 22 (71.0) | 90 (54.5) | |
| Dry nose/Crusting | 161 (42.3) | 108 (58.4) | 12 (38.7) | 41 (24.8) | |
| Sneezing/Runny nose | 152 (39.9) | 92 (49.7) | 11 (35.5) | 49 (29.7) | |
| Itchy nose | 200 (52.5) | 118 (63.8) | 13 (41.9) | 69 (41.8) | |
| Skin symptoms (one or more of the following) | 202 (53.0) | 121 (65.4) | 16 (51.6) | 65 (39.4) | |
| Skin itching | 156 (40.9) | 86 (46.5) | 12 (38.7) | 58 (35.2) | 0.095 |
| Skin rash/Dermatitis | 77 (20.2) | 54 (29.2) | 6 (19.4) | 17 (10.3) | |
| Acne/Increased pore size | 105 (27.6) | 79 (42.7) | 10 (32.3) | 16 (9.7) | |
| Pressure-related symptoms (one or more of the following) | 261 (68.5) | 158 (85.4) | 21 (67.7) | 82 (49.7) | |
| Nasal/facial pain | 155 (40.7) | 93 (50.3) | 15 (48.4) | 47 (28.5) | |
| Redness zygoma/forehead | 158 (41.5) | 101 (54.6) | 11 (35.5) | 46 (27.9) | |
| Decubitus lesions at zygoma/forehead | 54 (14.2) | 36 (19.5) | 5 (16.1) | 13 (7.9) | |
| Redness nosebridge | 180 (47.2) | 114 (61.6) | 13 (41.9) | 53 (32.1) | |
| Decubitus lesions at nosebridge | 50 (13.1) | 39 (21.1) | 4 (12.9) | 7 (4.2) | |
| Nasal dysmorphism | 46 (12.1) | 26 (14.1) | 4 (12.9) | 16 (9.7) | 0.453 |
| Auricular pain | 166 (43.6) | 121 (65.4) | 10 (32.3) | 35 (21.2) | |
| Ocular symptoms | 133 (34.9) | 83 (44.9) | 11 (35.5) | 39 (23.6) | |
| Head itching | 106 (27.8) | 73 (39.5) | 6 (19.4) | 27 (16.4) | |
| Worsening of allergy | 53 (13.9) | 36 (19.5) | 6 (19.4) | 11 (6.7) | |
| Mood deflection | 135 (35.4) | 75 (40.5) | 10 (32.3) | 50 (30.3) | 0.126 |
| Panic attack | 37 (9.7) | 17 (9.2) | 3 (9.7) | 17 (10.3) | 0.940 |
Data are presented as n (%); bold is used to highlight significant P value (<0.05).
FIGURE 3Multivariate analysis on symptoms predictors in the entire cohort.
Self-adopted Preventive Measures and Need of Medical Specialistic Consultation by General Population for PPE-Related Symptoms
| Entire Study Cohort ( | ||
| Self-adopted preventive measures, | ||
| Strips or facial dressing | 50 (13.1) | |
| Healing ointment | 27 (7.1) | |
| Emollient ointment | 108 (28.3) | |
| Frequent cleansing/facial peeling | 125 (37.5) | |
| Eye drops | 56 (14.7) | |
| Nasal rinse | 74 (19.4) | |
| Nasal ointment/spray | 39 (10.2) | |
| Painkillers | 13 (3.4) | |
| Need of medical specialistic consultation, | 18 (4.7) | |
| ENT visit | 9 (2.4) | |
| Ophthalmology visit | 3 (0.8) | |
| Dermatologic visit | 4 (1.0) | |
| Aesthetical visit | 4 (1.0) | |
| Psichological visit | 4 (1.0) | |
Data are presented as n (%).